阿尔茨海默病中的微生物代谢:从致病源到治疗潜力
Alejandro Borrego-Ruiz1, Juan J Borrego2
1Departamento de Psicología Social y de las Organizaciones, Universidad Nacional de Educación a Distancia (UNED), 28040 Madrid, Spain.
Current issues in molecular biology
|September 29, 2025
概括
肠道微生物群影响阿尔茨海默氏症 (AD) 病变的发生. 通过诸如益生菌之类的干预措施调节肠道微生物组,可以通过减少神经炎症和病理来减缓AD的进展.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 越来越多的证据将肠道微生物组与阿尔茨海默病 (AD) 的发展联系起来.
- 肠道微生物组失生症与AD病原发生有关,涉及微生物代谢物和微生物群-肠道-大脑轴.
- 本综述综合了当前关于肠道微生物组在阿尔茨海默病中的作用的研究,重点关注机制和治疗潜力.
研究的目的:
- 检查将肠道微生物组失调与阿尔茨海默病相关的证据.
- 探索微生物代谢组在AD病变发生过程中的机械作用.
- 审查针对AD的潜在治疗策略,以肠道微生物群为目标.
主要方法:
- 进行了叙述性的,非系统的文献综述.
- 在PubMed,Scopus和Web of Science数据库中进行了搜索.
- 文献搜索发生在2025年6月至7月期间.
主要成果:
- 阿尔茨海默病与肠道微生物多样性减少和细菌组成改变有关.
- 肠道微生物组的改变与炎症相关,并可能通过微生物群-肠道-大脑轴加剧AD.
- 穿越障碍的微生物产品引发神经炎症并促进AD病理;短链脂肪酸调节这些过程. 针对微生物组的治疗方法非常有前途.
结论:
- 肠道微生物组显著影响阿尔茨海默病的发病.
- 调节肠道微生物组为减缓AD进展提供了潜在的治疗益处.
- 需要进一步的研究,以建立有效的临床干预措施,以阿尔茨海默病的肠道微生物群为目标.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
1.2K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.4K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
